المؤلفون: Raffaele Ornello, Anna P. Andreou, Eleonora De Matteis, Tim P. Jürgens, Mia T. Minen, Simona Sacco

المصدر: EBioMedicine, Vol 99, Iss , Pp 104943- (2024)

مصطلحات موضوعية: Resistant migraine, Refractory migraine, CGRP, Non-pharmacological treatments, Migraine-related disability, Medicine, Medicine (General), R5-920

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2352396423005091Test; https://doaj.org/toc/2352-3964Test

الوصول الحر: https://doaj.org/article/d58613bd500946509c4df158a26e2d39Test

المؤلفون: G. R. Tabeeva, O. V. Kosivtsova, N. A. Kovalchuk, T. A. Orlyuk, Г. Р. Табеева, О. В. Косивцова, Н. А. Ковальчук, Т. А. Орлюк

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 2 (2024); 76-86 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 2 (2024); 76-86 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-2

مصطلحات موضوعية: купирование приступов мигрени, resistant migraine, refractory migraine, preventive treatment, relief of migraine attacks, резистентная мигрень, рефрактерная мигрень, профилактическое лечение

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/2235/1653Test; GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):954-76. doi:10.1016/S1474-4422(18)30322-3. Erratum in: Lancet Neurol. 2021 Dec;20(12):e7.; Ornello R, Andreou AP, De Matteis E, et al. Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine. 2024 Jan;99:104943. doi:10.1016/j.ebiom.2023.104943. Epub 2023 Dec 23.; Groth M, Katsarava Z, Ehrlich M. Results of the gErman migraine PatIent Survey on medical Care and prOPhylactic treatment Experience (EPISCOPE). Sci Rep. 2022 Mar 17;12(1):4589. doi:10.1038/s41598-022-08716-w; Goadsby PJ, Schoenen J, Ferrari MD, et al. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006 Sep;26(9):1168-70. doi:10.1111/j.1468-2982.2006.01173.x; Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010 Oct;50(9):1499-506. doi:10.1111/j.1526-4610.2010.01764.x; Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi:10.1177/0333102417738202; Schulman EA, Peterlin BL, Lake AE 3rd, et al. Defining refractory migraine: results of the RHSIS Survey of American Headache Society members. Headache. 2009 Apr;49(4):509-18. doi:10.1111/j.1526-4610.2009.01370.x. Epub 2009 Feb 25.; Sacco S, Lampl C, Maassen van den Brink A, et al; Burden and Attitude to Resistant and Refractory (BARR) Study Group. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J Headache Pain. 2021 May 18;22(1):39. doi:10.1186/s10194-021-01252-4; Schulman EA, Brahin EJ. Refractory headache: historical perspective, need, and purposes for an operational definition. Headache. 2008 Jun;48(6):770-7. doi:10.1111/j.1526-4610.2008.01135.x. Epub 2008 May 9.; Pozo-Rosich P, Lucas C, Watson DPB, et al. Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study. Pain Ther. 2021 Dec;10(2):1691-708. doi:10.1007/s40122-021-00331-3. Epub 2021 Oct 13.; De Matteis E, Guglielmetti M, Ornello R, et al. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother. 2020 Jun;20(6):627-41. doi:10.1080/14737175.2020.1772758. Epub 2020 Jun 2.; Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain. 2022 Jun 11;23(1):67. doi:10.1186/s10194-022-01431-x; Sacco S, Bendtsen L, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019 Jan 16;20(1):6. doi:10.1186/s10194-018-0955-y. Erratum in: J Headache Pain. 2019 May 23;20(1):58.; Lambru G, Hill B, Murphy M, et al. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020 Jun 1;21(1):61. doi:10.1186/s10194-020-01127-0; Reisman EE Jr. The use of experimental suppositories in treating refractory migraine. Am Pract Dig Treat. 1952 Apr;3(4):308-10.; Schulman EA, Lake AE 3rd, Goadsby PJ, al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008 Jun;48(6):778-82. doi:10.1111/j.1526-4610.2008.01132.x. Epub 2008 May 14.; Martelletti P, Katsarava Z, Lampl C, et al. Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. 2014 Aug 28;15(1):47. doi:10.1186/1129-2377-15-47; Saper J, Lake A 3rd, Lipton R. Staging headache cases: reconciling the coplexity of a case with the required intensity of treatment. Headache. 2007 Jan;47(1):90-3. doi:10.1111/j.1526-4610.2006.00634.x; Loder E, Biondi D. Disease modification in migraine: a concept that has come of age? Headache. 2003 Feb;43(2):135-43. doi:10.1046/j.1526-4610.2003.03033.x; Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, doubleblinded, controlled study. Cephalalgia. 2012 Dec;32(16):1165-79. doi:10.1177/0333102412462642. Epub 2012 Oct 3. Erratum in: Cephalalgia. 2014 Oct;34(11):944.; Saper JR, Dodick DW, Silberstein SD, et al; ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011 Feb;31(3):271-85. doi:10.1177/0333102410381142. Epub 2010 Sep 22.; Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020 Jun 16;21(1):76. doi:10.1186/s10194-020-01130-5; Филатова ЕГ, Осипова ВВ, Табеева ГР и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):4-14. doi:10.14412/2074-2711-2020-4-4-14; Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi:10.14412/2074-2711-2022-5-109-116; Evers S, Afra J, Frese A, et al; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migrainerevised report of an EFNS task force. Eur J Neurol. 2009 Sep;16(9):968-81. doi:10.1111/j.1468-1331.2009.02748.x; D'Amico D, Leone M, Grazzi L, Bussone G. When should “chronic migraine” patients be considered “refractory” to pharmacological prophylaxis? Neurol Sci. 2008 May;29 Suppl 1:S55-8. doi:10.1007/s10072-008-0888-3; Ковальчук НА, Кирьянова ЕА, Табеева ГР. Приверженность терапии пациентов с мигренью (по данным интернет-опроса). Неврология, нейропсихиатрия, психосоматика. 2021;13(4):81-7. doi:10.14412/2074-2711-2021-4-81-87; Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020 Apr 7;21(1):32. doi:10.1186/s10194-020-01102-9; Табеева ГР. Плацебо-аналгезия. Неврология, нейропсихиатрия, психосоматика. 2018;10(3):108-15. doi:10.14412/2074-2711-2018-3-108-115; Mitsikostas DD. Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep. 2012 Apr;12(2):132-7. doi:10.1007/s11910-011-0245-4; Smitherman TA, Penzien DB, Maizels M. Anxiety disorders and migraine intractability and progression. Curr Pain Headache Rep. 2008 Jun;12(3):224-9. doi:10.1007/s11916-008-0039-9; Breslau N, Lipton RB, Stewart WF, et al. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology. 2003 Apr 22;60(8):1308-12. doi:10.1212/01.wnl.0000058907.41080.54; Edvinsson L, Haanes KA. Views on migraine pathophysiology: Where does it start? Neurol Clin Neurosci. 2020;8:120-7.; Maizels M. Does the neurobiology of migraine make migraine patients “difficult”? Headache. 2012 Nov-Dec;52(10):1612. doi:10.1111/j.1526-4610.2012.02258.x; Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012 Nov;13(8):615-24. doi:10.1007/s10194-012-0479-9. Epub 2012 Sep 25.; Radat F. What is the link between migraine and psychiatric disorders? From epidemiology to therapeutics. Rev Neurol (Paris). 2021 Sep;177(7):821-6. doi:10.1016/j.neurol.2021.07.007. Epub 2021 Jul 27.; Silvestro M, Tessitore A, Scotto di Clemente F, et al. Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand. 2021 Sep;144(3):325-33. doi:10.1111/ane.13472. Epub 2021 May 21.; Hinchey SA, Jackson JL. A cohort study assessing difficult patient encounters in a walkin primary care clinic, predictors and outcomes. J Gen Intern Med. 2011 Jun;26(6):588-94. doi:10.1007/s11606-010-1620-6. Epub 2011 Jan 25.; Chalmer MA, Rasmussen AH; International Headache Genetics Consortium; 23andme Research Team; Kogelman LJA, Olesen J, Hansen TF. Chronic migraine: Genetics or environment? Eur J Neurol. 2021 May;28(5):1726-36. doi:10.1111/ene.14724. Epub 2021 Jan 27.; Schulte LH, Allers A, May A. Hypothalamus as a mediator of chronic migraine: Evidence from high-resolution fMRI. Neurology. 2017 May 23;88(21):2011-6. doi:10.1212/WNL.0000000000003963. Epub 2017 Apr 26.; Strother LC, Srikiatkhachorn A, Supronsinchai W. Targeted Orexin and Hypothalamic Neuropeptides for Migraine. Neurotherapeutics. 2018 Apr;15(2):377-90. doi:10.1007/s13311-017-0602-3; Santoro JD, Moon PK, Han M, et al. Early Onset Diffusion Abnormalities in Refractory Headache Disorders. Front Neurol. 2022 Jun 14;13:898219. doi:10.3389/fneur.2022.898219; Egorova N, Benedetti F, Gollub RL, Kong J. Between placebo and nocebo: Response to control treatment is mediated by amygdala activity and connectivity. Eur J Pain. 2020 Mar;24(3):580-92. doi:10.1002/ejp.1510. Epub 2019 Dec 12.; Goadsby PJ, Holland PR. An Update: Pathophysiology of Migraine. Neurol Clin. 2019 Nov;37(4):651-71. doi:10.1016/j.ncl.2019.07.008; Silberstein SD, Calhoun AH, Lipton RB, et al; EVENT Study Group. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016 Aug 2;87(5):529-38. doi:10.1212/WNL.0000000000002918. Epub 2016 Jul 13.; Табеева ГР, Осипова ВВ, Филатова ЕГ и др. Диагностика и лечение лекарственноиндуцированной головной боли: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):4-13. doi:10.14412/2074-2711-2022-1-4-13; Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022 Oct 12;23(1):133. doi:10.1186/s10194-022-01502-z; Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al; MOTS Investigators. Patient-Centered Treatment of Chronic Migraine With Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial. Neurology. 2022 Apr 5;98(14):e1409-e1421. doi:10.1212/WNL.0000000000200117. Epub 2022 Feb 15.; Lipton RB, Buse DC, Nahas SJ, et al. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023 Dec;270(12):5692-710. doi:10.1007/s00415-023-11880-2. Epub 2023 Aug 24.; Табеева ГР, Филатова ЕГ, Амелин АВ и др. Альтернативные и комплементарные методы лечения мигрени. Неврология, нейропсихиатрия, психосоматика. 2024;16(1):4-15. doi:10.14412/2074-2711-2024-1-4-15; Bae JY, Sung HK, Kwon NY, et al. Cognitive Behavioral Therapy for Migraine Headache: A Systematic Review and MetaAnalysis. Medicina (Kaunas). 2021 Dec 28;58(1):44. doi:10.3390/medicina58010044; Aditya S, Rattan A. Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review. Saudi J Med Med Sci. 2023 Jan-Mar;11(1):11-8. doi:10.4103/sjmms.sjmms_95_22. Epub 2023 Jan 14.; Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ. 2010 Sep 29;341:c4871. doi:10.1136/bmj.c4871; Coppola G, Magis D, Casillo F, et al. Neuromodulation for Chronic Daily Headache. Curr Pain Headache Rep. 2022 Mar;26(3):267-78. doi:10.1007/s11916-022-01025-x. Epub 2022 Feb 7.; Lloyd JO, Hill B, Murphy M, et al. Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis. J Headache Pain. 2022 Jun 6;23(1):63. doi:10.1186/s10194-022-01428-6; Casucci G, Villani V, Cologno D, D'Onofrio F. Polytherapy for migraine prophylaxis. Neurol Sci. 2012 May;33 Suppl 1:S147-50. doi:10.1007/s10072-012-1060-7; Joshi S, Tepper SJ, Lucas S, et al. A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management. Headache. 2021 Jun;61(6):838-53. doi:10.1111/head.14135; D'Amico D. Controversies in migraine: monotherapy. Neurol Sci. 2012 May;33 Suppl 1:S141-5. doi:10.1007/s10072-012-1059-0; Alex A, Armand CE. Rational Polypharmacy for Migraine. Pract Neurol. 2022 May:30-4.; Silberstein SD, Dodick D, Freitag F, et al. Pharmacological approaches to managing migraine and associated comorbidities – clinical considerations for monotherapy versus polytherapy. Headache. 2007 Apr;47(4):585-99. doi:10.1111/j.1526-4610.2007.00760.x; Peterlin BL, Calhoun AH, Siegel S, Mathew NT. Rational combination therapy in refractory migraine. Headache. 2008 Jun;48(6):805-19. doi:10.1111/j.1526-4610.2008.01142.x; Ailani J, Blumenfeld AM. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache. 2022 Jan;62(1):106-8. doi:10.1111/head.14244. Epub 2021 Dec 7.; Pellesi L, Do TP, Ashina H, et al. Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale? Headache. 2020 Jun;60(6):1056-65. doi:10.1111/head.13843. Epub 2020 May 21.; Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022 Feb;42(2):108-18. doi:10.1177/03331024211053571. Epub 2021 Nov 7.; Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). J Headache Pain. 2019 May 23;20(1):60. doi:10.1186/s10194-019-1009-9; Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338-50. doi:10.1038/s41582-018-0003-1; Jackson JL, Cogbill E, Santana-Davila R, et al. A Comparative Effectiveness MetaAnalysis of Drugs for the Prophylaxis of Migraine Headache. PLoS One. 2015 Jul 14;10(7):e0130733. doi:10.1371/journal.pone.0130733; Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther. 2009 Mar;85(3):283-8. doi:10.1038/clpt.2008.203. Epub 2008 Nov 5.; Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia. 2017 Apr;37(5):470-85. doi:10.1177/0333102416678382. Epub 2016 Nov 12.; Pavelic AR, Wöber C, Riederer F, Zebenholzer K. Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data. Cells. 2022 Dec 29;12(1):143. doi:10.3390/cells12010143; Wang X, Wen D, He Q, et al. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J Headache Pain. 2022 Sep 8;23(1):105. doi:10.1186/s10194-022-01472-2; Raffaelli B, Kalantzis R, Mecklenburg J, et al. Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study. Front Neurol. 2020 May 28;11:417. doi:10.3389/fneur.2020.00417; Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018 Sep;38(10):1611-21. doi:10.1177/0333102418788347. Epub 2018 Jul 8.; Al-Hassany L, Lyons HS, Boucherie DM, et al; European Headache Federation School of Advanced Studies (EHF-SAS). The sense of stopping migraine prophylaxis. J Headache Pain. 2023 Feb 16;24(1):9. doi:10.1186/s10194-023-01539-8; Andreou AP, Fuccaro M, Hill B, et al. Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis. J Headache Pain. 2022 Nov 4;23(1):139. doi:10.1186/s10194-022-01507-8; https://nnp.ima-press.net/nnp/article/view/2235Test

الإتاحة: https://doi.org/10.14412/2074-2711-2024-2-76-86Test
https://doi.org/10.14412/2074-2711-2024-2Test
https://doi.org/10.1016/S1474-4422Test(18)30322-3
https://doi.org/10.1016/j.ebiom.2023.104943Test
https://doi.org/10.1038/s41598-022-08716-wTest
https://doi.org/10.1111/j.1468-2982.2006.01173.xTest
https://doi.org/10.1111/j.1526-4610.2010.01764.xTest
https://doi.org/10.1177/0333102417738202Test
https://doi.org/10.1111/j.1526-4610.2009.01370.xTest
https://doi.org/10.1111/j.1526-4610.2008.01135.xTest

المؤلفون: Sara Bottiroli, Rosaria Greco, Valentina Franco, Annamaria Zanaboni, Michela Palmisani, Gloria Vaghi, Grazia Sances, Roberto De Icco, Cristina Tassorelli

المصدر: International Journal of Molecular Sciences, Vol 25, Iss 3, p 1893 (2024)

مصطلحات موضوعية: resistant migraine, endocannabinoid system, personality disorders, psychological comorbidities, depression, Biology (General), QH301-705.5, Chemistry, QD1-999

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1422-0067/25/3/1893Test; https://doaj.org/toc/1661-6596Test; https://doaj.org/toc/1422-0067Test

الوصول الحر: https://doaj.org/article/579a3bef0279461e951786fdd9391bbaTest

المؤلفون: Raffaele Ornello, Bianca Raffaelli

المصدر: Frontiers in Neurology, Vol 14 (2023)

مصطلحات موضوعية: resistant migraine, refractory migraine, migraine prevention, migraine treatment, clinical trials, real-world evidence, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fneur.2023.1291439/fullTest; https://doaj.org/toc/1664-2295Test

الوصول الحر: https://doaj.org/article/8aa9fb5b7fb140a0b79fd376df22da50Test

المؤلفون: Jennifer Robblee

المصدر: Frontiers in Neurology, Vol 14 (2023)

مصطلحات موضوعية: refractory migraine, intractable migraine, chronic migraine, chronic daily headache, resistant migraine, diagnosis, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fneur.2023.1263535/fullTest; https://doaj.org/toc/1664-2295Test

الوصول الحر: https://doaj.org/article/7e3e639927c74f09b25aafdc3033005aTest

المؤلفون: Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner, Giorgio Lambru

المصدر: The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-9 (2022)

مصطلحات موضوعية: Erenumab, Chronic migraine, Resistant migraine, CGRP, Monoclonal antibodies, Medicine

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1129-2369Test; https://doaj.org/toc/1129-2377Test

الوصول الحر: https://doaj.org/article/0585fd94935644d48509129b2bd79bd4Test

المؤلفون: Hasan Hodaj, Jean-François Payen, Gerard Mick, Laurent Vercueil, Enkelejda Hodaj, Anne Dumolard, Bénédicte Noëlle, Chantal Delon-Martin, Jean-Pascal Lefaucheur

المصدر: Brain Stimulation, Vol 15, Iss 2, Pp 441-453 (2022)

مصطلحات موضوعية: Chronic migraine, Neuromodulation, Prophylactic treatment, Resistant migraine, Transcranial direct current stimulation, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S1935861X22000407Test; https://doaj.org/toc/1935-861XTest

الوصول الحر: https://doaj.org/article/07a421ecfd0b461a971f481367db6679Test

المؤلفون: Mayo, Zach, Keating, Christopher

المصدر: Department of Physical Therapy Faculty Papers

مصطلحات موضوعية: chiari malformations, postural tachycardia syndrome, exercise training, physical therapy rehabilitation, craniocervical fusion, manual therapist, resistant migraine, chronic non-specific neck pain, Medicine and Health Sciences, Physical Therapy, Rehabilitation and Therapy

وصف الملف: application/pdf

العلاقة: https://jdc.jefferson.edu/ptfp/36Test; https://jdc.jefferson.edu/context/ptfp/article/1036/viewcontent/Mayo_2023._Manual_Therapy_and_Exercise_for_the_Management_of_Chronic_Neck_Pain_With_Multiple_Neurovascular_Comorbidities__1_.pdfTest

الإتاحة: https://jdc.jefferson.edu/ptfp/36Test
https://jdc.jefferson.edu/context/ptfp/article/1036/viewcontent/Mayo_2023._Manual_Therapy_and_Exercise_for_the_Management_of_Chronic_Neck_Pain_With_Multiple_Neurovascular_Comorbidities__1_.pdfTest

المؤلفون: Simona Sacco, Christian Lampl, Antoinette Maassen van den Brink, Valeria Caponnetto, Mark Braschinsky, Anne Ducros, Patrick Little, Patricia Pozo-Rosich, Uwe Reuter, Elena Ruiz de la Torre, Margarita Sanchez Del Rio, Alexandra J. Sinclair, Paolo Martelletti, Zaza Katsarava, On behalf of the Burden and Attitude to Resistant and Refractory (BARR) Study Group

المصدر: The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-10 (2021)

مصطلحات موضوعية: Migraine, Resistant migraine, Refractory migraine, Migraine care, Medicine

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1129-2369Test; https://doaj.org/toc/1129-2377Test

الوصول الحر: https://doaj.org/article/7f47e162ba404dc98e99802a6fd4a987Test

المؤلفون: Bottiroli, Sara, Greco, Rosaria, Franco, Valentina, Zanaboni, Annamaria, Palmisani, Michela, Vaghi, Gloria, Sances, Grazia, De Icco, Roberto, Tassorelli, Cristina

المساهمون: Bottiroli, Sara, Greco, Rosaria, Franco, Valentina, Zanaboni, Annamaria, Palmisani, Michela, Vaghi, Gloria, Sances, Grazia, De Icco, Roberto, Tassorelli, Cristina

مصطلحات موضوعية: depression, endocannabinoid system, personality disorder, psychological comorbiditie, resistant migraine

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38339171; info:eu-repo/semantics/altIdentifier/wos/WOS:001160391500001; volume:25; issue:3; journal:INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; https://hdl.handle.net/11571/1491815Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85184691791

الإتاحة: https://doi.org/10.3390/ijms25031893Test
https://hdl.handle.net/11571/1491815Test